GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

OS Therapies OSTX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.92

-7.99%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$28.8m

FY2020FY2025

Free cash flow

−$14.24bn

FY2020FY2025

Shareholders' equity

−$6.1m

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Gross profit−$363,085−$2,780−$4,220−$805−$1.2m−$4,250
Research and development$16.36bn$2.8m$3.2m$3.3m$2.2m$602
Operating income−$28.7m−$6.8m−$4.3m−$4.4m−$4.8m−$5,647
Net income−$28.8m−$8.9m−$7.8m−$6.3m−$7.4m−$6,027
Diluted earnings per share-0.98-0.07-0.39-0.63-0.55-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assets$6.8m$5.5m$798,082$509,105$325,891$1.68bn
Cash and short-term investments$269,830$5.5m$38,982$171,480$80,788$1.23bn
Total liabilities$12.9m$4.7m$24.8m$18.1m$11.8m$8.00bn
Debt—$6.0m$14.6m$10.3m$7.1m$6.77bn
Shareholders' equity−$6.1m$811,487−$24.0m−$17.6m−$11.5m−$6.33bn
Shares outstanding29m124m20m10m13m44m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−$14.24bn−$7.3m−$3.0m−$3.8m−$4.4m−$2.41bn
Capital spending−$466,423———−$11,934−$2.0m
Free cash flow−$14.24bn−$7.3m−$3.0m−$3.8m−$4.4m−$2.42bn
Dividends paid—−$31.3m————

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Gross profit−$124,938−$124,938−$124,938−$124,938−$112,514−$695−$1,390—
Operating income−$8.6m−$10.3m−$12.0m−$6.9m−$4.8m−$5.0m−$3.0m−$2.4m
Net income−$8.6m−$10.4m−$13.5m−$6.9m−$4.5m−$3.9m−$3.0m−$2.9m
Diluted earnings per share-0.20-0.24-0.46-0.24-0.16-0.13-0.02-0.02
Cash from operations−$5.0m−$4.0m−$3.0m−$4.0m−$2.0m−$3.0m−$2.0m−$3.38bn
Total assets$9.9m$7.3m$6.8m$9.0m$10.3m$4.2m$5.5m$2.0m
Cash and short-term investments$205,035$917,552$269,830$1.9m$2.8m$3.0m$5.5m$1.9m
Debt—$1.3m——————
Shareholders' equity−$10.8m−$10.8m−$6.1m$4.7m$6.8m−$4.2m$811,487−$707,127

Growth per year

Compound annual rate

3 years5 years10 years
Operating income86.2%451.1%—
Net income66.3%444.2%—

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings-1.4-59.6

Share price return

Finished calendar years

20252024
Return-61%63%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.